nivolumab,tegafur,oxaliplatin,oteracil,gimeracil,capecitabine
ono pharma,nordic group,otsuka,bms
['nivo', 'attraction-5']
 attraction-5: nivo + ctx as adjuvant for stage iii gc/gej #asco23 phs-3 , 755 pts 3-yr rfs rate 68.4% vs 65.3% primary efficacy endpoint of rfs not met in all comers, better efficacy in pdl-1+ tumors 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology